ClinicalTrials.gg
CompletedNCT04003012Updated Oct 20, 2026Results posted

Pain Control in Pediatric Oncology: Utility of EMLA Cream vs Lidocaine Injection in Lumbar Punctures

A Phase 4 interventional study of EMLA and Lidocaine in Leukemia-Lymphoma, sponsored by CAMC Health System. Completed at 1 site in United States. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by CAMC Health System · Phase 4, Interventional, and Supportive care

How we know

Updated Oct 20, 2026Posted results revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Study summary

A common procedure in children with cancer is the spinal tap, or lumbar puncture (LP), in which a needle is inserted into the spinal canal. In this population, LPs are most commonly performed to collect cerebrospinal fluid (CSF, the liquid surrounding the brain and spinal cord) for diagnostic testing, and to inject medications including chemotherapy. Local analgesic (pain control medicine) during pediatric LP procedures is underutilized and not standardized. The first local analgesic routinely used for LP procedures was lidocaine injection. The discovery of the topical EMLA (lidocaine 2.5%/prilocaine 2.5%) cream, approved by the FDA for local skin use in pediatric patients, has provided an additional option for local LP analgesia. A comparison between topical EMLA vs lidocaine injection for LP pain control in the pediatric population has not been performed. Pediatric oncology patients often require serial LPs for diagnostics purposes and/or chemotherapy delivery. Due to a lack of standardization of LP analgesia in this population, the investigators have designed a prospective, single-blind, randomized control crossover trial to examine EMLA vs. lidocaine injection in reducing pain associated with LP in children being treated for leukemia or lymphoma.

02

Conditions studied

  • Leukemia-Lymphoma
03

In context

Lead sponsor

CAMC Health System is the lead sponsor of 47 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric cancer patients (aged 3-18) with a diagnosis of leukemia or lymphoma
  • Patients are expected to receive serial (i.e. > 1) LP as outpatients in Charleston Area Medical Center Children's Cancer Center in the course of 12 months for diagnostic and/or treatment purposes

Exclusion criteria

Exclusion Criteria:

  • Patients not in the age range
  • Non-cancer patients
  • Allergy to amide anesthetics
  • Patients treated with class I and III anti-arrhythmic drugs (eg, amiodarone, bretylium, sotalol, dofetilide)
  • Patients with congenital or idiopathic methemoglobinemia
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    EMLA

    The patient will receive 5 grams EMLA cream at the site of the lumbar puncture at least 60 minutes prior to procedure. The site of EMLA application will be covered with Tegaderm dressing.

    Drug: EMLA

  • Active comparator
    Lidocaine

    The patient will receive sham-EMLA cream (a fragrance-free hypoallergenic moisturizer cream) will be applied at least 60 minutes per standard protocol with Tegaderm dressing.- Following conscious sedation, the patient will receive lidocaine 1% injection (\~1-2ml) at the appropriate site 30-60 seconds prior to LP needle insertion.

    Drug: Lidocaine

Interventions

06

What researchers measure

Primary outcomes

  1. Post Lumbar Puncture Pain Score at 30-60 Minutes

    Wong-Baker Faces Pain Rating Scale assessed 30-60 minutes following lumbar puncture. Wong-Baker Faces Pain Rating Scale shows a series of six faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable". Based on the faces and written descriptions, the patient chooses the face that best describes their level of pain, with higher the number, greater the pain.

    Time frame: 30-60 minutes after lumbar puncture

  2. Post Lumbar Puncture Pain Score at 24 Hours

    Wong-Baker Faces Pain Rating Scale assessed 30-60 minutes following lumbar puncture. Wong-Baker Faces Pain Rating Scale shows a series of six faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable". Based on the faces and written descriptions, the patient chooses the face that best describes their level of pain, with higher the number, greater the pain.

    Time frame: 24 hours after lumbar puncture

Secondary outcomes

  1. Post Lumbar Puncture PRN Pain Medication Usage

    Use of PRN or "as needed" pain medicine by the patient was determined. Patients with parent/guardian assistance were asked to record the "as needed" pain control medication, acetaminophen. the patient used within the 24 hours after lumber puncture. Counts of patients using acetaminophen in the 24 hours following lumber puncture are reported.

    Time frame: 24 hours following lumbar puncture

07

Results

Posted Mar 9, 2023

Participant flow

10 patients were screen and enrolled in the study

Participant flow — Overall Study
MilestoneEMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar PunctureLidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar Puncture
Started55
Completed55
Not completed00

Outcome measures

PrimaryPost Lumbar Puncture Pain Score at 30-60 Minutes

Wong-Baker Faces Pain Rating Scale assessed 30-60 minutes following lumbar puncture. Wong-Baker Faces Pain Rating Scale shows a series of six faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable". Based on the faces and written descriptions, the patient chooses the face that best describes their level of pain, with higher the number, greater the pain.

Time frame:
30-60 minutes after lumbar puncture
Reported as:
Median · score on a scale
Post Lumbar Puncture Pain Score at 30-60 Minutes
score on a scaleEMLALidocaine Injection
Post Lumbar Puncture Pain Score at 30-60 Minutes0 (0 to 0)0 (0 to 0)
SecondaryPost Lumbar Puncture PRN Pain Medication Usage

Use of PRN or "as needed" pain medicine by the patient was determined. Patients with parent/guardian assistance were asked to record the "as needed" pain control medication, acetaminophen. the patient used within the 24 hours after lumber puncture. Counts of patients using acetaminophen in the 24 hours following lumber puncture are reported.

Time frame:
24 hours following lumbar puncture
Reported as:
Count of participants · Participants
Post Lumbar Puncture PRN Pain Medication Usage
ParticipantsEMLALidocaine
Post Lumbar Puncture PRN Pain Medication Usage12
PrimaryPost Lumbar Puncture Pain Score at 24 Hours

Wong-Baker Faces Pain Rating Scale assessed 30-60 minutes following lumbar puncture. Wong-Baker Faces Pain Rating Scale shows a series of six faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable". Based on the faces and written descriptions, the patient chooses the face that best describes their level of pain, with higher the number, greater the pain.

Time frame:
24 hours after lumbar puncture
Reported as:
Median · score on a scale
Post Lumbar Puncture Pain Score at 24 Hours
score on a scaleEMLALidocaine Injection
Post Lumbar Puncture Pain Score at 24 Hours0 (0 to 8)0 (0 to 8)

Adverse events

Collected over 7 days for each intervention. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EMLA0/10 (0%)0/10 (0%)0/10 (0%)
Lidocaine Injection0/10 (0%)0/10 (0%)0/10 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)EMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar PunctureLidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar PunctureTotal
Median5 (3.5 to 14)6 (4 to 11)5.5 (4 to 11)
Sex: Female, Male
Sex: Female, Male(Participants)EMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar PunctureLidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar PunctureTotal
Female134
Male426
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar PunctureLidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar PunctureTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5510
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)EMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar PunctureLidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar PunctureTotal
United States5510
08

Study locations

1 site
  • CAMC - Women and Children's Hospital
    Charleston, West Virginia 25302, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Jul 2021, 24 months.

Results were first posted in Mar 2023, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jul 1, 2019
StartActual
Jul 19, 2019
Primary completionActual
Jul 20, 2021
CompletionActual
Jul 20, 2021
Results first posted
Mar 9, 2023
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 20, 2026
Primary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedPost Lumbar Puncture Pain Score at 30-60 MinutesTime frame: 30-60 minutes after lumbar puncture
  • AddedPost Lumbar Puncture Pain Score at 24 HoursTime frame: 24 hours after lumbar puncture
  • RemovedPost Lumbar Puncture Pain: Wong-Baker Faces Pain Rating ScaleTime frame: , pain will be assessed at 30 - 60 minutes after waking up after lumbar puncture and 24 hours after lumbar puncture
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Posted results revised
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedPost Lumbar Puncture Pain Score at 30-60 MinutesTime frame: 30-60 minutes after lumbar puncture
    • AddedPost Lumbar Puncture Pain Score at 24 HoursTime frame: 24 hours after lumbar puncture
    • RemovedPost Lumbar Puncture Pain: Wong-Baker Faces Pain Rating ScaleTime frame: , pain will be assessed at 30 - 60 minutes after waking up after lumbar puncture and 24 hours after lumbar puncture
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04003012
Lead sponsor
CAMC Health System
Responsible party
Stephanie Thompson (Study Coordinator, CAMC Health System) — Principal investigator
First posted
Jul 1, 2019
Start date
Jul 19, 2019
Primary completion
Jul 20, 2021
Completion
Jul 20, 2021
Results posted
Mar 9, 2023
Last update
Oct 20, 2026

Study contacts

Mohamad Badawi, MD
principal investigator · WVU-Charleston and CAMC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Prilocaine

Start the discussion